View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Orion Group Holdings Reports 4th Quarter and Full Year 2025 Results an...

Orion Group Holdings Reports 4th Quarter and Full Year 2025 Results and Initiation of 2026 Guidance HOUSTON, March 03, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company” or “Orion”), a leading specialty construction company, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Highlights for the year ended December 31, 2025: ($ in millions, except EPS) Revenue of $852 million, GAAP net income of $2.5 million or $0.06 per diluted share, Adjusted EBITDA of $45 million and Adjusted EPS of $0.25 per diluted shareCash ...

 PRESS RELEASE

Myriad Commercially Launches Precise MRD with Select Community Oncolog...

Myriad Commercially Launches Precise MRD with Select Community Oncologists Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the ™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. “The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. By detecting ctDNA at extremely low...

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 28, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 27, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Counting Clicks: January '26 Traffic Trends

Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr

 PRESS RELEASE

Fossil Group, Inc. Announces Date for Fourth Quarter and Full Year 202...

Fossil Group, Inc. Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call RICHARDSON, Texas, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) announced today that it will report fourth quarter and full year 2025 financial results after market close on Wednesday, March 11, 2026, followed by a conference call to discuss the results at 5:00 p.m. ET the same day. The call can be accessed live on the Company’s investor relations website at /investors and will also be archived for replay. About Fossil Group, Inc. Fossil Group, Inc. is a gl...

 PRESS RELEASE

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact ...

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its TM (Molecular Residual Disease) Test, ® Prostate Cancer Prognostic Test and ® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification,...

 PRESS RELEASE

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Re...

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution Highlights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, H...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

FirstGene Study Demonstrates High Analytical Sensitivity and Specifici...

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test Analytical validation of FirstGene Multiple Prenatal Screen published in Clinical Chemistry SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced the publication of the analytical validation of the in Clinical Chemistry. The showed that each component of the test had exceptional sensitivity and specificity. Titled “Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene condit...

 PRESS RELEASE

Cabot Corporation Announces Production Capabilities in Asia Pacific fo...

Cabot Corporation Announces Production Capabilities in Asia Pacific for Circular Reinforcing Carbons Powered by its EVOLVE Sustainable Solutions Technology Platform Company now has capabilities across key regions to advance sustainable offerings  BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- (NYSE: CBT) today announced the availability to produce in Asia Pacific its circular reinforcing carbons powered by its EVOLVE Sustainable Solutions technology platform. As such, Cabot's manufacturing facilities in Cilegon, Indonesia and Tianjin, China have successfully validated their ability to produc...

 PRESS RELEASE

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial...

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 16, 2026 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in molecular testing and precision medicine, will hold its fourth quarter and full year 2025 earnings conference call at 4:30 pm ET on Monday, Feb. 23, 2026. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of ...

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Consumers Still Traveling; Neutral, $260 PT

Figure 1. 4Q25 ResultsSource: Company reports, Wedbush Estimates, Visible Alpha ConsensusExpedia reported strong 4Q results with gross bookings and adj. EBITDA well ahead of estimates. Room night growth in the quarter of +8.8% Y/Y (94mm) was above St. estimates by ~130bps. Gross bookings of $27.0B

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Agents Work, Humans Travel; Neutral, $130 PT

Figure 1. 4Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusAirbnb reported strong 4Q results and provided a healthy outlook for 1Q. Nights and Experiences booked growth in 4Q of +15.9% Y/Y was ~560bps above Street estimates. Revenue and adj. EBITDA were ahead of expectations

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt
 PRESS RELEASE

Donna Karan New York Presents The Edit, the Spring 2026 Campaign Featu...

Donna Karan New York Presents The Edit, the Spring 2026 Campaign Featuring Adriana Lima, Joan Smalls and Grace Elizabeth NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Donna Karan New York continues its reemergence with The Edit: a curated fashion campaign shaped by three women whose presence transcends trend, age, and moment. Adriana Lima, Joan Smalls, and Grace Elizabeth bring their distinct points of view to the brand’s design DNA, selecting and styling a personal edit from the wider collection for an intimate dialogue between women and their wardrobes. Highlighting the talents’ pe...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch